TRODELVY（戈沙妥组单抗,sacituzumab govitecan-hziy）

On April 22, 2020, the US Food and Drug Administration (FDA) accelerated the approval of Trodelvy (R0 Wa-prepared monoclonal antibody) for adult patients with metastatic triple-negative breast cancer (mTNBC) who had received at least two therapies before. Trodelvy is the first ADC drug specially approved by FDA to treat relapsed or refractory mTNBC, and it is also the first anti-Trop-2 ADC drug approved by FDA.
TRODELVY (R0 sacituzumab govitecan-hziy)_) _ Hong Kong Jimin Pharmaceutical

【 Indications and uses of Trodelvy (Sacituzumab Govitecan-Hziy) 】:
For adult patients with metastatic triple negative breast cancer (mTNBC) who have received at least two therapies before.

[dosage and administration method of Trodelvy (Sacituzumab Govitecan-Hziy].
1. This drug is a prescription drug, and it is an intravenous infusion; It needs to be prepared and administered by professional medical staff.
2. Give this medicine once a week on the 1st and 8th day of the 21-day treatment cycle.
3. The first dose of drip time is more than 3 hours. If the patient can tolerate the first dose well, the subsequent drip time can be controlled at 1 to 2 hours.
4. Before each administration, medication should be used to prevent infusion reactions, such as nausea and vomiting.
5. During and at least 30 minutes after each infusion, patients should be monitored for adverse reactions.
6. If patients have transfusion-related reactions, medical staff should slow down the drip speed or temporarily stop infusion; If there is a life-threatening infusion reaction, you may stop using this medicine permanently.
7. The duration of treatment is determined by the medical staff.

[contraindication of Trodelvy (Sacituzumab Govitecan-Hziy)]
It is forbidden for patients who are allergic to any component of this medicine.

[Adverse reaction of Trodelvy (Sacituzumab Govitecan-HZiy)]
Common adverse reactions are: fatigue; Decreased red blood cell count; Hair loss; Constipation; Rash; Loss of appetite; Stomach area (abdomen) pain, etc.
This medicine can cause serious adverse reactions, such as:
1. Neutropenia, the symptoms may include: fever, cold, cough, shortness of breath, burning or pain when urinating.
2. Severe diarrhea
3. Severe and life-threatening allergic reactions: swelling of the face, lips, tongue or throat; Urticaria; Skin rash or flushing; Dyspnea or asthma; Dizziness, feeling weak or fainting; Chill or tremble and chill; Have a fever, etc.
4. Nausea and vomiting
The above adverse reactions are discussed in more detail in other sections of the manual.